MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer

Trial Profile

MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms MOUNTAINEER
  • Most Recent Events

    • 09 Mar 2018 According to a Seattle Genetics media release, Cascadian Therapeutics has been acquired by Seattle Genetics, and this acquisition provides the Global Rights of Tucatinib to Seattle Genetics.
    • 08 Feb 2018 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.
    • 04 Jan 2018 According to a Cascadian Therapeutics media release, company plans to report interim results from this study during 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top